NurExone Biologic Inc.
NRX.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -39.32% | -82.00% | -109.77% | -8.04% | -27.40% |
| Total Depreciation and Amortization | 223.08% | 186.67% | 1,200.00% | 0.00% | 116.67% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -2.19% | 1,204.17% | 66.50% | 184.68% | -14.89% |
| Change in Net Operating Assets | 247.54% | 157.73% | -466.67% | -59.00% | 421.05% |
| Cash from Operations | -22.64% | 32.70% | -174.09% | -3.68% | -25.00% |
| Capital Expenditure | 96.72% | 86.72% | 31.34% | -30,200.00% | -2,950.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -95.65% | -- | -- |
| Cash from Investing | 97.18% | 86.72% | -2.27% | -30,200.00% | -3,450.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 85.71% | 62.50% | 12.50% | 27.27% | -600.00% |
| Issuance of Common Stock | 10,506.67% | -79.28% | 345.12% | 19.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -454.78% | 20.00% | -- |
| Cash from Financing | 3,513.64% | -79.31% | 96.67% | 19.79% | 4,500.00% |
| Foreign Exchange rate Adjustments | 340.74% | -118.18% | -1,366.67% | -- | 400.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 173.56% | -104.13% | -202.82% | -47.53% | -22.88% |